On March 28, 2016 Kitov Pharmaceuticals (NASDAQ and TASE: KTOV), reported that TyrNovo Ltd., a company majority-owned by Kitov, will present preclinical data on TyrNovo’s anti-tumor resistance drug candidate NT219 in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017, to be held April 1-5, at the Walter E. Washington Convention Center in Washington, D.C (Press release, Kitov Pharmaceuticals , MAR 27, 2017, View Source [SID1234518293]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Hadas Reuveni, TyrNovo’s founder and chief technology officer, will discuss recent promising results demonstrating NT219’s efficacy in patient-derived xenograft models (PDX) in mice.
NT219 is a small molecule that blocks two feedback pathways highly involved in drug resistance, IRS and STAT3. Combined treatment of NT219 with drugs targeting EGFR, such as Tagrisso and Erbitux, overcame acquired resistance of colon, lung, and head-and-neck cancers in PDX models.
Details on the poster presentations are as follows:
Title: Comprehensive high-throughput screen for combination therapies to block acquired resistance to targeted drugs
Session: PO.ET04.05 – Reversal of Drug Resistance
Location: Section 6
When: Monday, Apr 3, 2017, 8:00 AM – 12:00 PM ET
Poster Board Number: 1190 / 5
About TyrNovo
TyrNovo Ltd. is developer of novel small molecules in the oncology therapeutic field which is majority owned by Kitov Pharmaceuticals (NASDAQ/TASE: KTOV). TyrNovo is developing NT219, a potential oncology combination product. NT219 is a small molecule that presents a new concept in cancer therapy. In combination with various approved oncology drugs, NT219 demonstrated potent anti-tumor effects and increased survival in various cancer models, including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is through the prevention of acquired resistance in tumors and by regression of resistant tumors. For more information on TyrNovo please visit View Source